Trials / Completed
CompletedNCT03686488
TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find out if the combination of TAS 102 and Ramucirumab is safe and effective in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TAS 102 | TAS 102 35 mg will be administered orally twice daily every 2 weeks. |
| DRUG | Ramucirumab 10 MG/ML Intravenous Solution [CYRAMZA] | Ramucirumab 8 milligrams/kilogram will be administered as a 60 minute intravenous (IV) infusion every 2 weeks. |
Timeline
- Start date
- 2018-12-20
- Primary completion
- 2022-01-19
- Completion
- 2024-05-31
- First posted
- 2018-09-27
- Last updated
- 2026-03-02
- Results posted
- 2023-03-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03686488. Inclusion in this directory is not an endorsement.